Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837428 | 0.96 | MEN1 (0.55) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3121131 | 0.95 | MEN1 (0.54) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL837415 | 0.92 | TSHR (0.49) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL19066313 | 0.87 | ALDH1A1 (0.57) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL836795 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AHSD17B10HTT | |
| SCHEMBL3103672 | 0.87 | ALDH1A1 (0.44) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL23255226 | 0.86 | TSHR (0.56) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3185456 | 0.86 | ALDH1A1 (0.43) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL835813 | 0.84 | ALDH1A1 (0.42) | TSHRALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3187590 | 0.84 | TSHR (0.46) | TSHRALDH1A1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
| WO-2016119570-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | 上海珊顿医药科技有限公司 | 2016-08-04 | — | — | WO | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1912991-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007017261-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | TSHR 200/4885ALDH1A1 1397/4885MEN1 1560/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | TSHR 612/4885ALDH1A1 305/4885MEN1 3009/4885 |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | NLRP3, REN, SLC5A1 | TSHR 3210/4885ALDH1A1 627/4885MEN1 2275/4885 |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | REN, NLRP3, SLC5A1 | TSHR 2830/4885ALDH1A1 657/4885MEN1 2223/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | TSHR 612/4885ALDH1A1 305/4885MEN1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.